Posted by Michael Wonder on 02 Mar 2017
Alnylam receives European Medicines Agency PRIME designation for accelerated assessment of givosiran, an investigational RNAi therapeutic for the treatment of acute hepatic porphyrias
1 March 2017 - Alnylam Pharmaceuticals announced today that the EMA has granted access to its Priority Medicines (PRIME) scheme for givosiran (ALN-AS1), an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyrias.
The purpose of the PRIME initiative is to bring treatments to patients faster by enhancing the EMA's support for the development of medicines for diseases where there is an unmet medical need and where early clinical data show potential to benefit patients.
